You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
In the context of a growing criticism on the influence of the pharmaceutical industry on physicians, scientists, or politicians, Conflict of Interest and Medicine offers a comprehensive analysis of the conflict of interest in medicine anchored in the social sciences, with perspectives from sociology, history, political science, and law. Based on in-depth empirical investigations conducted within different territories (France, the European Union, and the United States) the contributions analyze the development of conflict of interest as a social issue and how it impacts the production of medical knowledge and expertise, physicians’ work and their prescriptions, and also the framing of healt...
Annotation This book is a controversial skewering of how doctors and the medical industry turn healthy people into patients.
An argument that technology accelerates biological discovery, with case studies ranging from chromosome discovery with early microscopes to how DNA replicates using radioisotope labels. Engineering has been an essential collaborator in biological research and breakthroughs in biology are often enabled by technological advances. Decoding the double helix structure of DNA, for example, only became possible after significant advances in such technologies as X-ray diffraction and gel electrophoresis. Diagnosis and treatment of tuberculosis improved as new technologies—including the stethoscope, the microscope, and the X-ray—developed. These engineering breakthroughs take place away from the ...
The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA's science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the state of regulatory science and to consider approaches for enhancing it.
Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.
The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health. The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals. In this no-holds-barred exposé, Dr. John Abrams...
2 Vol set.
THE NEW COLOR OF MEDICINE HUNDREDS OF DIAGRAMS AND CLINICAL PHOTOS INTEGRATED INTO THE TEXT – FOR THE FIRST TIME IN FULL COLOR *This description refers to the single-volume of Harrison's Principles of Internal Medicine, 16/e. The Harrison's name is synonymous with internal medicine. HPIM continues to be the most authoritative and #1 selling medical textbook throughout the world. From its unique section on signs and symptoms through to the most comprehensive coverage of most all conditions seen by physician’s, Harrison's is the internal medicine reference of choice. Harrison's 16th Edition features new, expanded, revised and updated material on the key topics in medical practice today. Fr...